Figure 4 - uploaded by Smita Mahapatra
Content may be subject to copyright.
Hemoglobin electrophoresis (capillary zone) showing sickle cell disease.  

Hemoglobin electrophoresis (capillary zone) showing sickle cell disease.  

Source publication
Article
Full-text available
Cerebrovascular accidents are common in elderly people, but rare in children. The stroke developing due to basal ganglion infarct in an infant with sickle cell disease (homozygous) is extremely rare. To the best of our knowledge, not a single case has been repoted till date. We are reporting a 10 months old infant developing stroke after a mild fal...

Similar publications

Article
Full-text available
Ventricular tachycardia (VT) is a crucial cause of sudden cardiac death (SCD) and a primary cause of mortality and morbidity in patients with structural cardiac disease. VT includes clinical disorders varying from benign to life-threatening. Most life-threatening episodes are correlated with coronary artery disease, but the risk of SCD varies in ce...
Article
Full-text available
Objective: Sickle cell disease (SCD) is a lifelong condition characterized by pain, which is associated with reduced health-related quality of life (HRQL). Data suggest that patients with SCD vary in how they cope and their neurocognitive abilities. This study aimed to characterize executive functioning and pain coping styles in children with SCD...
Article
Full-text available
Deregulation of the trucking industry and significantly lowered transportation costs led to large, widespread, and plausibly exogenous reductions in inventory for U.S. firms, with consequent increased supply-chain disruption (SCD) costs. We find evidence that increased SCD costs help explain the puzzling long-term trend of increasing average U.S. f...
Article
Full-text available
Antiplatelet treatment is a potential therapeutic approach for sickle cell disease (SCD). Ticagrelor inhibits platelet aggregation and is approved for adults with acute coronary syndrome and following myocardial infarction. HESTIA1 (NCT02214121) was a two‐part, phase 2 dose‐finding study generating ticagrelor exposure, platelet inhibition, and safe...